{
  "docId": "019de071-41d7-735b-bdce-76898f0847d2",
  "docSlug": "eaafde7daeccaea38d88b7264ade91c5",
  "documentTitle": "Erasca | IPO Presentation Deck | 46 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 46,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a Gantt-style chart to represent clinical trial progress across multiple programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-41d7-735b-bdce-76898f0847d2/10",
  "deckHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2",
  "deckJsonHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2.json",
  "deckAnchorHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.4,
        "x": 0.17,
        "y": 0.88
      },
      "kind": "image",
      "text": "Legend for modalities: small molecule, large molecule, protein degrader",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90bd9d36-3984-4771-8af5-fe0a1d8b8c47",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "Erasca also has two additional discovery programs, ERAS-9 and ERAS-11, which are small molecule inhibitor programs targeting SOS1 and MYC, respectively.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d3fd317-7da3-4d7c-92f6-0218c3ba05d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.15,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Phase 1 clinical trial of ERAS-007 evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD)...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a97ff0a7-aca8-46c1-b303-72e5916b1148",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.95,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "table",
      "text": "Pipeline table with columns: Program, Modality, Indication, Discovery, IND-enabling, Phase 1, Phase 2, Phase 3, Erase Cancer Strategy, Worldwide Rights",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a708a250-943c-46f9-bb85-feb726e20553",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Deep modality-agnostic RAS/MAPK pathway-focused pipeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d86b567-53bf-4270-93ab-24552cf8bfe7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "7e9d1347-7c98-40d3-9c14-7a6177db92f9",
      "evidence": "The pipeline table uses horizontal bars to represent the development stage of each program.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 11,
      "from": 9,
      "beatId": "652c3261-8969-4cab-bbc5-f0a084cb4ac2",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents Erasca's pipeline of RAS/MAPK pathway inhibitors, including ERAS-007 and ERAS-601, as a promising solution for cancer treatment.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}